186 related articles for article (PubMed ID: 37934630)
1. Oral Manganese Chloride Tetrahydrate: A Novel Magnetic Resonance Liver Imaging Agent for Patients With Renal Impairment: Efficacy, Safety, and Clinical Implication.
Brismar TB; Geisel D; Kartalis N; Madrazo BL; Persson Hedman H; Norlin A
Invest Radiol; 2024 Feb; 59(2):197-205. PubMed ID: 37934630
[TBL] [Abstract][Full Text] [Related]
2. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status.
Stojanov D; Aracki-Trenkic A; Benedeto-Stojanov D
Neuroradiology; 2016 May; 58(5):433-41. PubMed ID: 26873830
[TBL] [Abstract][Full Text] [Related]
3. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
[TBL] [Abstract][Full Text] [Related]
4. Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?
Layne KA; Wood DM; Dargan PI
Clin Toxicol (Phila); 2020 Mar; 58(3):151-160. PubMed ID: 31663374
[No Abstract] [Full Text] [Related]
5. A New Era in Magnetic Resonance Contrast Media.
Runge VM; Heverhagen JT
Invest Radiol; 2024 Feb; 59(2):105-107. PubMed ID: 37862104
[TBL] [Abstract][Full Text] [Related]
6. Brain gadolinium deposition after administration of gadolinium-based contrast agents.
Kanda T; Oba H; Toyoda K; Kitajima K; Furui S
Jpn J Radiol; 2016 Jan; 34(1):3-9. PubMed ID: 26608061
[TBL] [Abstract][Full Text] [Related]
7. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
[TBL] [Abstract][Full Text] [Related]
8. Safety issues related to intravenous contrast agent use in magnetic resonance imaging.
Ponrartana S; Moore MM; Chan SS; Victoria T; Dillman JR; Chavhan GB
Pediatr Radiol; 2021 May; 51(5):736-747. PubMed ID: 33871726
[TBL] [Abstract][Full Text] [Related]
9. Divalent Manganese Complexes as Potential Replacements for Gadolinium-Based Contrast Agents.
Caravan P
Invest Radiol; 2024 Feb; 59(2):187-196. PubMed ID: 38038701
[TBL] [Abstract][Full Text] [Related]
10. Effect of Renal Function on Gadolinium-Related Signal Increases on Unenhanced T1-Weighted Brain Magnetic Resonance Imaging.
Cao Y; Zhang Y; Shih G; Zhang Y; Bohmart A; Hecht EM; Prince MR
Invest Radiol; 2016 Nov; 51(11):677-682. PubMed ID: 27272543
[TBL] [Abstract][Full Text] [Related]
11. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis.
McDonald JS; McDonald RJ
Magn Reson Imaging Clin N Am; 2020 Nov; 28(4):497-507. PubMed ID: 33040991
[TBL] [Abstract][Full Text] [Related]
12. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.
Davies J; Siebenhandl-Wolff P; Tranquart F; Jones P; Evans P
Arch Toxicol; 2022 Feb; 96(2):403-429. PubMed ID: 34997254
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
Do C; DeAguero J; Brearley A; Trejo X; Howard T; Escobar GP; Wagner B
Kidney360; 2020 Jun; 1(6):561-568. PubMed ID: 34423308
[TBL] [Abstract][Full Text] [Related]
14. High signal intensity in dentate nucleus and globus pallidus on unenhanced T1-weighted MR images in three patients with impaired renal function and vascular calcification.
Barbieri S; Schroeder C; Froehlich JM; Pasch A; Thoeny HC
Contrast Media Mol Imaging; 2016 May; 11(3):245-50. PubMed ID: 26929131
[TBL] [Abstract][Full Text] [Related]
15. Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging.
Marasini R; Thanh Nguyen TD; Aryal S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jan; 12(1):e1580. PubMed ID: 31486295
[TBL] [Abstract][Full Text] [Related]
16. Brain MRI and clinical exam findings in women with multiple gadolinium-based contrast agent (GBCA) exposures due to screening breast MRIs.
Myers KS; Yousem DM; Mills KA; Gad K; Niri SG; Bienko N; Munro CA
Clin Imaging; 2022 Dec; 92():57-62. PubMed ID: 36202017
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol CB; Hiremath S
Can J Kidney Health Dis; 2018; 5():2054358118778573. PubMed ID: 29977584
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
Bäuerle T; Saake M; Uder M
Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
[TBL] [Abstract][Full Text] [Related]
19. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation.
Stanescu AL; Shaw DW; Murata N; Murata K; Rutledge JC; Maloney E; Maravilla KR
Pediatr Radiol; 2020 Mar; 50(3):388-396. PubMed ID: 31989188
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
